Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 10, 2005. The report primarily details corporate actions regarding share repurchases and changes in directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Share Repurchase Price: 1,355.72 pence per share.
- ShareReward Plan Price: £13.605 per share.
- Treasury Shares Held: 96,293,000 shares (post-transaction).
- Shares in Issue: 5,848,094,430 shares (excluding Treasury shares).
Material Changes
The following material changes occurred on or around June 10, 2005:
- Share Buyback: The company purchased 735,000 ordinary shares for treasury purposes, utilizing authority granted at the Annual General Meeting on May 25, 2005.
- Employee Trust Transfer: The GlaxoSmithKline Employee Trust transferred 3,277 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Share Acquisition: Director Mr. J S Heslop acquired 20 ordinary shares (10 via personal contribution and 10 via company matching) under the ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a procedural report of share movements and director interests.
Investor Verification Checklist
- Verify the total number of treasury shares held (96,293,000) against the company's latest capital structure reports.
- Confirm the remaining authority for share buybacks following the purchase of 735,000 shares.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding the 3,277 shares transferred.
- Check the total share count in issue (5,848,094,430) to ensure accuracy in diluted share calculations.